检索结果 - Hong Jae Chon
- Showing 1 - 20 results of 36
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma 由 Chan Kim, Hannah Yang, Il Hwan Kim, Beodeul Kang, Hyeyeong Kim, Hyunho Kim, Won Suk Lee, Sanghoon Jung, Ho Yeong Lim, Jaekyung Cheon, Hong Jae Chon
出版 2022Artigo -
16
Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis 由 Jaekyung Cheon, Hong Jae Chon, Yeonghak Bang, Neung Hwa Park, Jung Woo Shin, Kang Mo Kim, Han Chu Lee, Joo‐Ho Lee, Changhoon Yoo, Baek‐Yeol Ryoo
出版 2020Artigo -
17
-
18
Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer 由 Yu Seong Lee, Won Suk Lee, Chang Woo Kim, Seung Joon Lee, Hannah Yang, So Jung Kong, John Ning, Kyung-Mee Yang, Beodeul Kang, Woo Ram Kim, Hong Jae Chon, Chan Kim
出版 2020Artigo -
19
STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer 由 Seung Joon Lee, Hannah Yang, Woo Ram Kim, Yu Seong Lee, Won Suk Lee, So Jung Kong, Hye Jin Lee, Jeong Hun Kim, Jaekyung Cheon, Beodeul Kang, Hong Jae Chon, Chan Kim
出版 2021Artigo -
20
相关主题
Medicine
Internal medicine
Cancer
Oncology
Immunotherapy
Gastroenterology
Hepatocellular carcinoma
Chemotherapy
Nivolumab
Atezolizumab
Bevacizumab
Cancer research
Immunology
Biology
Immune system
Confidence interval
Sorafenib
Cancer immunotherapy
Lenvatinib
Tumor microenvironment
Biochemistry
Hazard ratio
Immune checkpoint
Adverse effect
Aerospace engineering
Cohort
Colorectal cancer
Engineering
Pathology
Receptor